• P-ISSN 0973-7200 E-ISSN 2454-8405
  • Follow us

Journal of Pharmaceutical Research

Article

Cost Variation Analysis of Hypolipidemic Drugs Currently Available in Indian Pharmaceutical Market
  • VIEWS 289
  • PDF 112

Journal of Pharmaceutical Research

DOI: 10.18579/jopcr/v23.2.39

Year: 2024, Volume: 23, Issue: 2, Pages: 83-88

Original Article

Cost Variation Analysis of Hypolipidemic Drugs Currently Available in Indian Pharmaceutical Market

Prajnyan Prasad Kalita1,∗, Hiteswar Saikia2, Meghali Chaliha3

1Post Graduate Trainee, Department of Pharmacology, Assam Medical College and Hospital, Dibrugarh, Assam, India
2Assistant Professor, Department of Pharmacology, Assam Medical College and Hospital, Dibrugarh, Assam, India
3Professor and Head of the Department, Department of Pharmacology, Assam Medical College and Hospital, Dibrugarh, Assam, India

*Corresponding Author
Email: [email protected]

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

42% of all fatalities worldwide resulting from non-communicable diseases (NCD) are attributable to cardiovascular illnesses. The availability of several brands and generic medications causes a wide range in the pricing at which they are sold. This study was conducted to raise awareness among health care workers and patients about the cost difference between different brands of the same hypolipidemic drug, so that, if possible, a cheaper effective brand can be prescribed to ensure better patient adherence. Maximum retail price (MRP) of various hypolipidemic drugs of same strength and dosage forms manufactured by different pharmaceutical companies were obtained from various online and offline sources. The maximum and minimum cost of 10 tablets/capsules were noted. The cost ratio and percentage cost variation were calculated for single drug and fixed dose combinations. The ceiling price (as per DPCO) of hypolipidemics (as per national list of essential medicines) was compared with their maximum cost. Maximum cost variation observed in case of single drug was Atorvastatin 10mg (3043.9393%), and in case of FDC was seen in Rosuvastatin 10mg + Aspirin75mg (561.341%). This study led us to the conclusion that the majority of hypolipidemic medications should be governed by DPCO in order to lessen the economic load of healthcare services on the Indian population.

Keywords: Pharmacoeconomic, Cost variation, Hypolipidemic, Statins

References

  3. Roth GA, Forouzanfar MH, Moran AE, Barber R, Nguyen G, Feigin VL, et al. Demographic and Epidemiologic Drivers of Global Cardiovascular Mortality. New England Journal of Medicine. 2015;372(14):1333–1341. Available from: https://www.nejm.org/doi/10.1056/NEJMoa1406656
  4. The India State-Level Disease Burden Initiative. Public Health Foundation of India, Institute for Health Metrics and Evaluation. Available from: https://phfi.org/the-work/research/the-india-state-level-disease-burden-initiative/
  5. Prabhakaran D, Jeemon P, Roy A. Cardiovascular Diseases in India: Current Epidemiology and Future Directions. Circulation. 2016;133(16):1605–1620. Available from: https://doi.org/10.1161/circulationaha.114.008729
  9. Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N, et al. 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Canadian Journal of Cardiology. 2021;37(8):1129–1150. Available from: https://doi.org/10.1016/j.cjca.2021.03.016
  10. Market Study on the Pharmaceutical Sector in India: Key Findings and Observations. (pp. 1-50) New Delhi, India. Competition Commission of India. 2021.
  11. Shankar PR, Subish P, Mishra P, Lalit M. Ambiguous pricing of Nepalese medicines. Journal of Institute of Medicine Nepal. 2006;28(3):35–38. Available from: https://www.nepjol.info/index.php/JIOM/article/view/627
  13. Sondarva DB, Hirpara HN. Cost variation analysis of hypolipidemic drugs currently available in Indian pharmaceutical market. International Journal of Basic & Clinical Pharmacology. 2020;9(1):69–76. Available from: https://doi.org/10.18203/2319-2003.ijbcp20195585
  14. Product Portfolio: Product and MRP List. Pharmaceuticals & Medical Devices Bureau of India. Available from: http://janaushadhi.gov.in/SortingView.aspx
  15. Rawat AU, Kumar P, Qasim M, Chauhan R, Mohsin M. A Cost Variation Analysis of Hypolipidemic Drugs Available in the Indian Market. International Journal of Research and Review. 2023;10(4): 2454–2237. Available from: https://www.ijrrjournal.com/IJRR_Vol.10_Issue.4_April2023/IJRR60.pdf
  16. Shinde M, Kushwah A. A Pharmacoeconomic Comparison of Cost Variation among Hypolipidemic Drugs Available in Indian Market. Pharmacology and Clinical Pharmacy Research. 2021;6(3):112–121. Available from: https://jurnal.unpad.ac.id/pcpr/article/view/32488/pdf
  17. Frazier LM, Brown JT, Divine GW, Fleming GR, Philips NM, Siegal WC, et al. Can Physician education lower the price of prescription drugs? A prospective control trial. Annals of Internal Medicine. 1991;115(2):116–121. Available from: https://doi.org/10.7326/0003-4819-115-2-116

Copyright

© 2024 Published by Krupanidhi College of Pharmacy. This is an open-access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by-nc-nd/4.0/) 

  • 06 August 2024

Year: 2024, Volume: 23, Issue: 2


More articles

DON'T MISS OUT!

Subscribe now for latest articles and news.